EGFR, HER2 & Receptor Tyrosine Kinases

Cat. No.

AT0067

CAS No.

1952272-74-0

Bemarituzumab

Bemarituzumab is a humanized IgG1 monoclonal antibody designed to selectively target and inhibit FGFR2b (fibroblast growth factor receptor 2b). By blocking the binding and activation of fibroblast growth factors to FGFR2b, Bemarituzumab effectively impedes cellular processes that contribute to tumor growth and proliferation. This antibody has demonstrated significant antitumor activity in clinical studies, particularly in the context of gastric and breast cancers, making it a valuable tool for research in oncology and targeted therapy development.

Cat. No.

AT0088

CAS No.

2226775-26-2

Tilvestamab

Synonyms: BGB149

Tilvestamab (BGB149) is a humanized monoclonal antibody specifically targeting the AXL receptor tyrosine kinase. By effectively blocking AXL-mediated signaling pathways, Tilvestamab significantly reduces Gas6-induced AXL activation in 786-0-Luc renal cell carcinoma (RCC) cells and subsequently inhibits AKT phosphorylation. This antibody is particularly valuable in cancer research focusing on conditions characterized by overexpression of AXL, such as renal cell carcinomas.

Cat. No.

AT0599

CAS No.

180288-69-1

Trastuzumab

Synonyms: Anti-Human HER2; Humanized Antibody

Trastuzumab is a humanized IgG1 monoclonal antibody specifically designed for targeting and neutralizing HER2, a protein overexpressed in certain invasive breast cancers. This antibody is crucial for research focused on HER2-positive metastatic breast cancer and HER2-positive gastric cancer, providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.

Cat. No.

AT0677

CAS No.

667901-13-5

Zalutumumab

Zalutumumab is a fully human IgG1 monoclonal antibody exhibiting high affinity for the epidermal growth factor receptor (EGFR). It specifically binds to domain III of EGFR, effectively blocking the receptor's interaction with its natural ligand, EGF. This interaction inhibits the receptor's activation by steric hindrance, preventing its transition to an active conformation. Zalutumumab demonstrates binding affinities with half-maximal effective concentrations (EC50) of 7 nM for the whole IgG and 19 nM for its Fab fragment. This antibody is primarily utilized in cancer research, providing a valuable tool for investigating EGFR's role in oncogenic processes and therapeutic interventions.

Cat. No.

AT0685

CAS No.

2213450-26-9

Petosemtamab

Synonyms: MCLA 158

Petosemtamab (MCLA 158) is a bifunctional monoclonal antibody targeting both EGFR and LGR5 with dissociation constants (Kd) of 0.22 nM and 0.86 nM, respectively. This antibody effectively blocks EGFR signaling and induces receptor degradation specifically in LGR5-positive cancer cells. Petosemtamab is primarily utilized in research focused on solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for investigating the pathophysiology and potential therapeutic strategies for these malignancies.

Cat. No.

AT0826

CAS No.

1005389-60-5

Dalotuzumab

Synonyms: MK-0646; h7C10

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody designed to specifically target the insulin-like growth factor 1 receptor (IGF-1R). This antibody functions by inhibiting the signaling pathways initiated by IGF-1 and IGF-2, which are commonly implicated in tumor cell proliferation. It effectively blocks IGF-1R autophosphorylation and subsequent phosphorylation of Akt, a critical node in the pro-survival signaling network. Additionally, Dalotuzumab promotes apoptosis and induces cell cycle arrest, further inhibiting cancer cell growth. Research has demonstrated that when used in conjunction with other anticancer agents, including statins, Dalotuzumab exhibits enhanced antitumor efficacy both in vitro and in vivo. This makes it a valuable tool for studies focused on cancer biology and therapeutic antibody development.

Cat. No.

AT0841

CAS No.

1365287-97-3

Emibetuzumab

Synonyms: LY2875358

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 subtype, designed to exhibit potent neutralizing and internalizing capabilities. This antibody effectively inhibits both hepatocyte growth factor (HGF)-dependent and HGF-independent MET pathway activations, thereby impeding tumor growth. Emibetuzumab is primarily utilized in cancer research studies, focusing on its therapeutic potential and mechanism of action in oncogenic signaling and tumor progression.

Cat. No.

AT0999

CAS No.

1262787-83-6

Patritumab

Synonyms: Human Anti-ERBB3 Recombinant Antibody

Patritumab is a recombinant human monoclonal antibody that specifically targets ERBB3, exhibiting neutralizing properties. This antibody effectively synergizes with Cetuximab to inhibit the phosphorylation of key signaling proteins including EGFR, HER2, HER3, ERK, and AKT. Through its action, Patritumab induces apoptosis and inhibits tumor growth, demonstrating significant efficacy in preclinical models of pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Patritumab is a valuable tool for research focused on the molecular mechanisms of cancer progression and therapeutic antibody development.

Cat. No.

AT1018

CAS No.

943453-46-1

Figitumumab

Synonyms: CP-751871

Figitumumab (CP-751871) is a potent, fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R). This antibody effectively inhibits the binding of IGF1 to IGF1R, demonstrating an inhibitory concentration (IC50) of 1.8 nM. Designed for high specificity and affinity, Figitumumab is utilized primarily in research focused on the modulation of growth factor signaling pathways.

Cat. No.

AT1168

CAS No.

2367012-88-0

Anbenitamab

Synonyms: KN-026

Anbenitamab (KN-026) is a bispecific antibody engineered to target extracellular domains II and IV of human HER2, effectively blocking both ligand-dependent and ligand-independent signaling pathways associated with this receptor. The inclusion of the IgG1 Fc fragment enhances its interaction with FcRγIIIa, facilitating robust antibody-dependent cell-mediated cytotoxicity (ADCC) and effectively inhibiting tumor cell proliferation. This antibody is primarily researched for its therapeutic potential in HER2-positive metastatic breast cancer (MBC).

Cat. No.

AT1498

CAS No.

1174900-84-5

Ficlatuzumab

Ficlatuzumab is a monoclonal antibody specifically designed to target human hepatocyte growth factor (HGF). This antibody effectively blocks the activation of the HGF/c-Met signaling pathway, crucial in modulating processes such as cell proliferation, migration, and invasion associated with cancer progression. By inhibiting the c-Met receptor-mediated activities, Ficlatuzumab serves as a potent therapeutic agent in the study and potential treatment of various cancers characterized by overactivation of this pathway.

Cat. No.

AT1521

CAS No.

1512559-37-3

Elgemtumab

Synonyms: LJM716

Elgemtumab (LJM716) is a fully human IgG monoclonal antibody designed to selectively target and bind to human epidermal growth factor receptor 3 (HER3). By binding to HER3, Elgemtumab effectively blocks both ligand-dependent and independent signal transduction pathways, thereby inhibiting cellular proliferation. This targeted mechanism demonstrates significant potential in anti-tumor therapies, making it a valuable tool for oncological research and therapeutic development.